New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease (Q33537438)

27 July 2017

1 reference

title

New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease (English)

1 reference

27 July 2017

1 reference

2

Meco G

1 reference

27 July 2017

Bonifati V

1

1 reference

27 July 2017

publication date

1 January 1999

1 reference

Pharmacology & Therapeutics

27 July 2017

published in

1 reference

27 July 2017

volume

81

1 reference

27 July 2017

issue

1

1 reference

27 July 2017

page(s)

1-36

1 reference

Absorption and Metabolism of Levodopa

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-Methoxy-4-hydroxy-D-mandelic acid, a urinary metabolite of norepinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone and fulminant hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Presence of two distinct catechol -O- methyltransferase activities in red blood cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Interactions between estrogens and catechol amines. 3. Studies on the methylation of catechol estrogens, catechol amines and other catechols by the ctechol-O-methyltransferases of human liver

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-O-Methyldopa, a New Precursor of Dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

How far are we in understanding the cause of Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

1 reference

7 January 2021

Peripheral aromaticl-amino acids decarboxylase inhibitor in parkinsonism. II. Effect on metabolism ofl-2-14C-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Clinical pharmacology of the new COMT inhibitor CGP 28,014

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol O-methyltransferase. 3. Mechanism of pyridoxal 5'-phosphate inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The purification and kinetic properties of liver microsomal-catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Human liver catechol-O-methyltransferase pharmacogenetics

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of dietary protein on striatal dopamine formation following L-dopa administration: An in vivo study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase inhibition increases striatal L-dopa and dopamine: an in vivo study in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Hormonal influences on erythrocyte catechol-O-methyl transferase activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of L-DOPA on the concentrations of free and sulfoconjugated catecholamines in plasma, cerebrospinal fluid, urine, and central and peripheral nervous system tissues of the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Nitrocatechol derivatives as inhibitors of catechol-O-methyltransferase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The metabolism of orally administered l-DOPA in Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Parkinsonism treated with 3-O-methyldopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Clinical pharmacokinetics of anti-parkinsonian drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of supplemental carbidopa on bioavailability of L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Clinical significance of the relationship between O-methyldopa levels and levodopa intake

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Clinical usefulness of apomorphine in movement disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Metabolic modification of Parkinson's disease and of chronic manganese poisoning

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of tolcapone on plasma and striatal apomorphine disposition in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kinetic studies on catechol O-methyltransferase. Product inhibition and the nature of the catechol binding site

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Depression and Parkinson's disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

A double-blind comparison of levodopa, madopa, and sinemet in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma DOPA response to levodopa administration in man: Effects of a peripheral decarboxylase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma normetanephrine for examination of extraneuronal uptake and metabolism of noradrenaline in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Potentiation of the l-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Systemic activity of orally administered L-dopa in the elderly Parkinson patient

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-O-methyldopa and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

IN-VITRO DECARBOXYLATION OF NEW PHENYLALANINE DERIVATIVES.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Does O-methyl-dopa play a role in levodopa-induced dyskinesias?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The inheritance of human erythrocyte catechol-O-methyltransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Erythrocyte catechol-O-methyltransferase activity in a Swedish population

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kinetics of purified catechol O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Roles of uptake1 and catechol-O-methyltransferase in removal of circulating catecholamines in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Dopamine visualized in the basal ganglia of living man.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Cognitive improvement during Tolcapone treatment in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

A susceptibility locus for Parkinson's disease maps to chromosome 2p13.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of 3-OM-dopa on monoamine metabolism in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Metabolism of 3,4-dihydroxyphenylalanine (l-DOPA) in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Chromosomal mapping of the human catechol-O-methyltransferase gene to 22q11.1----q11.2

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Electrophoretic analysis of low and high activity forms of catechol-O-methyltransferase in human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-O-methyldopa administration does not alter fluorodopa transport into the brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of catechol-O-methyltransferase inhibition on the plasma clearance of noradrenaline and the formation of 3,4-dihydroxyphenylglycol in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Regional brain kinetics of 6-fluoro-(beta-11C)-L-dopa and (beta-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The COMT inhibitor tolcapone potentiates the anticataleptic effect of Madopar in MPP(+)-lesioned mice

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

No Association between Parkinson's Disease and Low-Activity Alleles of CatecholO-Methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Purification and kinetic mechanism of human brain soluble catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Immunohistochemical demonstration of catechol-O-methyltransferase in mammalian brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Distribution of catechol-O-methyltransferase enzyme in rat tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase (COMT) in rat brain: immunoelectron microscopic study with an antiserum against rat recombinant COMT protein

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Could treatment with DOPS do for autonomic failure what DOPA did for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Low catechol-O-methyltransferase activity in a Saami population

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

High and low activity alleles of catechol-O-methyltransferase gene: ethnic difference and possible association with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The metabolism of L-3-0-methyldopa, aprecursor of dopa in man

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of 3,4-dihydroxyphenylpyruvic acid and L-glutamic acid on some pharmacokinetic parameters of L-dopa in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Cloning and Characterization of Human Placental Catechol--Methyltransferase cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase in Escherichia coli; purification and partial characterization of the enzyme.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Modification of levodopa effect by systemic decarboxylase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

1 reference

7 January 2021

Nigrostriatal function in humans studied with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

L-6-[18F]fluoro-dopa metabolism in monkeys and humans: biochemical parameters for the formulation of tracer kinetic models with positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Protein Intake and Treatment of Parkinson's Disease with Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

6-[18F]Fluoro-l-dihydroxyphenylalanine metabolism and positron emission tomography aftercatechol-O-methyltransferase inhibition in normal and hemiparkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Metabolism of levodopa in patients with Parkinson's disease. Radioactive and fluorometric assays

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma dopa concentrations after different preparations of levodopa in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kainic acid lesion of the striatum increases dopamine release but reduces 3-methoxytyramine level

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Inhibition of catechol-O-methyltransferase activity by two novel disubstituted catechols in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase activity in human and rat small intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Levodopa-induced dyskinesia: review, observations, and speculations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Pharmacokinetics of Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-O-methyldopa and the response to levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Short- and long-duration responses to levodopa during the first year of levodopa therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of catechol-O-methyl transferase inhibition on peripheral and central metabolism of 6-[18F]fluoro-L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The subacute levodopa test for evaluating long-duration response in parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-O-methyldopa blocks dopa metabolism in rat corpus striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-o-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase activity: a determinant of levodopa response.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma concentration of levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

L-dopa treatment failure: explanation and correction

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

1 reference

7 January 2021

Kinetic studies on the O-methylation of dopamine by human brain membrane-bound catechol O-methyltransferase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Localization of membrane-bound catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma levodopa, dopamine and therapeutic response following levodopa therapy of Parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

(-)-Deprenyl treatment of patients with Parkinson's disease does not affect erythrocyte catechol-O-methyl transferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Molecular cloning and characterization of rat liver catechol-O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behavior of levodopa in dogs and Parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Determination of catechol-O-methyltransferase activity in erythrocytes by high performance liquid chromatography with electrochemical detection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The presence of catechol-o-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of CGP 28014 on the in vivo release and metabolism of dopamine in the rat striatum assessed by brain microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Antioxidant properties of nitecapone (OR-462)

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity and comparison of the allele frequencies in the normal population and Parkinsonian patients in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Central action of benserazide after COMT inhibition demonstrated in vivo by PET

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Characterization of the rat catechol-O-methyltransferase gene proximal promoter: identification of a nuclear protein-DNA interaction that contributes to the tissue-specific regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Structure of the rat catechol-O-methyltransferase gene: separate promoters are used to produce mRNAs for soluble and membrane-bound forms of the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Purification and partial characterization of rat liver soluble catechol-O-methyltransferase.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta: comparison to the rat liver enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Purification methods of mammalian catechol-O-methyltransferases.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Expression of recombinant soluble and membrane-bound catechol O-methyltransferase in eukaryotic cells and identification of the respective enzymes in rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Drug-Induced Changes of Extracerebral Dopa Metabolism in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Patterns of clinical response and plasma dopa levels in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Acute Toxicity of Three New Selective COMT Inhibitors in Mice with Special Emphasis on Interactions with Drugs Increasing Catecholaminergic Neurotransmission

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of three types of catechol O-methylation inhibitors on L-3,4-dihydroxyphenylalanine-induced circling behaviour in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Kinetics of rat brain soluble catechol-O-methyltransferase and its inhibition by substrate analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Validation of assay of catechol-O-methyltransferase activity in human erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Pathogenesis of idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Cell-free synthesis of rat and human catechol O-methyltransferase. Insertion of the membrane-bound form into microsomal membranes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Crystal structure of catechol O-methyltransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Genetic factors in the etiology of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

2,4,5-Trihydroxyphenylacetic acid. Metabolite of L-3,4-dihydroxyphenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Active Transport of L-Dopa in the Intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Variability of L-Dopa Absorption in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Human erythrocyte catechol-o-methyltransferase: Correlation with lung and kidney activity

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Correlation of erythrocyte catechol-O-methyltransferase activity between siblings

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Is there a genetic susceptibility to idiopathic parkinsonism?

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

A twin study on three enzymes (DBH, COMT, MAO) of catecholamine metabolism. Correlations with MMPI.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Genes and parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2898%2900032-1

7 January 2021

10.1016/S0163-7258(98)00032-1

Identifiers

DOI

1 reference

27 July 2017

1 reference